Commission Regulation (EC) No 1024/2009 of 29 October 2009 on the authorisation and refusal of authorisation of certain health claims made on food and referring to the reduction of disease risk and to children’s development and health (Text with EEA relevance)
Data as of 2026-07-04 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗
The health claims set out in Annex I to this Regulation may be made on food on the Community market in compliance with the conditions set out in that Annex. Those health claims shall be included in a list of permitted claims referred to in Article 14(1) of Regulation (EC) No 1924/2006.
The health claims set out in Annex II to this Regulation shall not be included in the Community list of permitted claims as provided for in Article 14(1) of Regulation (EC) No 1924/2006. However, they may continue to be used for six months after the entry into force of this Regulation.
This Regulation shall enter into force on the 20th day following its publication in the Official Journal of the European Union .
ANNEX I PERMITTED HEALTH CLAIMS Application — Relevant provisions of Regulation (EC) No 1924/2006 Applicant — Address Nutrient, substance, food or food category Claim Conditions of use of the claim Conditions and/or restrictions of use of the food and/or additional statement or warning EFSA opinion reference Article 14(1)(a) health claim referring to a reduction of a disease risk Leaf Int and Leaf Holland, Hoevestein 26, 4903 SC Oosterhout NB, The Netherlands, and Leaf Suomi Oy, PO Box 25, FI-21381 Aura, Finland Chewing gum sweetened with 100 % xylitol Chewing gum sweetened with 100 % xylitol has been shown to reduce dental plaque. High content/level of dental plaque is a risk factor in the development of caries in children Information to the consumer that the beneficial effect is obtained with a consumption of 2-3 g of chewing gum sweetened with 100 % xylitol at least 3 times per day after the meals Q-2008-321 Article 14(1)(b) health claim referring to children’s development and health Danone SA, C/Buenos Aires, 21, 08029 Barcelona, Spain Phosphorus Phosphorus is needed for the normal growth and development of bone in children The claim can be used only for food which is at least a source of phosphorus as referred to in the claim SOURCE OF [NAME OF VITAMIN/S] AND/OR [NAME OF MINERAL/S] as listed in the Annex to Regulation (EC) No 1924/2006 Q-2008-217
ANNEX II REJECTED HEALTH CLAIMS Application — Relevant provisions of Regulation (EC) No 1924/2006 Nutrient, substance, food or food category Claim EFSA opinion reference Article 14(1)(b) health claim referring to children’s development and health Lactoral Lactoral helps to bring back the normal functioning of the alimentary tract during its microflora disturbances (for example in case of loose stools, after taking antibiotics, in case of intestinal disorders caused by enteric pathogens) EFSA-Q-2008-269 Article 14(1)(b) health claim referring to children’s development and health Lactoral Lactoral is recommended in order to improve the general immunity by maintaining the microbiological balance EFSA-Q-2008-477 Article 14(1)(b) health claim referring to children’s development and health Lactoral Lactoral helps to protect the alimentary system against enteric pathogens because of strong antagonistic properties and helps to build the natural intestinal barrier EFSA-Q-2008-478 Article 14(1)(b) health claim referring to children’s development and health Lactoral Lactoral helps to maintain natural intestinal microflora during travel, changing the climatic zone or a diet, especially in poor hygiene conditions EFSA-Q-2008-479 Article 14(1)(b) health claim referring to children’s development and health Lactoral Lactoral contains living probiotic bacteria with strong ability to intestinal tract colonisation, isolated from healthy, naturally fed infant EFSA-Q-2008-480 Article 14(1)(b) health claim referring to children’s development and health Mumomega® Mumomega® provides the nourishments that support healthy central nervous system development EFSA-Q-2008-328 Article 14(1)(b) health claim referring to children’s development and health Efalex® Efalex® may help maintain coordination EFSA-Q-2008-121 Article 14(1)(b) health claim referring to children’s development and health Efalex® Efalex® may help maintain concentration EFSA-Q-2008-317 Article 14(1)(b) health claim referring to children’s development and health Efalex® Efalex® may help maintain and support brain development and function EFSA-Q-2008-318 Article 14(1)(b) health claim referring to children’s development and health Efalex® Efalex® may help maintain learning ability EFSA-Q-2008-319 Article 14(1)(b) health claim referring to children’s development and health Efalex® Efalex® may help maintain and support eye development and function EFSA-Q-2008-320 Article 14(1)(b) health claim referring to children’s development and health Eye q baby® Eye q baby® provides the nourishments that support healthy central nervous system development EFSA-Q-2008-119 Article 14(1)(b) health claim referring to children’s development and health Eye q® Eye q® provides the nourishments that help children to maintain healthy brain functions EFSA-Q-2008-329 Article 14(1)(b) health claim referring to children’s development and health Eye q® Eye q® provides the nourishments that help children to maintain concentration levels EFSA-Q-2008-330
Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.